These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Medicaid drug price requirement hurts public hospitals. Wagner L Mod Healthc; 1992 Aug; 22(32):21. PubMed ID: 10119779 [No Abstract] [Full Text] [Related]
3. Lost sleep... Pontious JM J Okla State Med Assoc; 2002 Aug; 95(8):523. PubMed ID: 12185985 [No Abstract] [Full Text] [Related]
4. Collateral damage. Providers face negative fallout from the war on drugmakers. Taylor M Mod Healthc; 2001 Jun; 31(24):30-3. PubMed ID: 11430166 [No Abstract] [Full Text] [Related]
5. PMA (Pharmaceutical Manufacturers Association) finances grassroots coalition to fight changes in Medicaid formularies. Gatty B Hosp Formul; 1993 Aug; 28(8):714, 713. PubMed ID: 10127749 [No Abstract] [Full Text] [Related]
6. FDA action spurs change in groups' drug programs. Perry PA Hosp Mater Manage; 1989 Nov; 14(11):1, 13-4. PubMed ID: 10295911 [No Abstract] [Full Text] [Related]
7. What really sells a drug today? Wein PJ; Hoffmann RP Hosp Pharm; 1988 May; 23(5):478-9. PubMed ID: 10287639 [No Abstract] [Full Text] [Related]
8. Formulary for trouble. Alliance, data firm in duel on drug-buying information. Hensley S Mod Healthc; 1998 Mar; 28(10):26-7. PubMed ID: 10177178 [No Abstract] [Full Text] [Related]
9. The other side of the fence: hospital P&T committee members' role in drug selection. Archambault GF Med Mark Media; 1978 May; 13(5):48, 50, 52 passim. PubMed ID: 10307029 [No Abstract] [Full Text] [Related]
10. Prospective reimbursement and DRGs: implications for formulary management. Enright SM Hosp Formul; 1983 Oct; 18(10):989-90, 999-1000. PubMed ID: 10310246 [No Abstract] [Full Text] [Related]
11. Drug price inflation slows but competition is limited. Hosp Purch Manage; 1983 Aug; 8(8):13-4. PubMed ID: 10261667 [No Abstract] [Full Text] [Related]
12. Formulary management to reduce cost: P & T committee strategies. Roberts MJ; Summerfield MR Hosp Formul; 1986 Apr; 21(4):481-3, 488-92. PubMed ID: 10276289 [TBL] [Abstract][Full Text] [Related]
13. Opinion: price controls on prescription drugs. Franks B N J Med; 2004 Apr; 101(4):56, 55. PubMed ID: 15103791 [No Abstract] [Full Text] [Related]
14. Drug Price Index declines as prices weaken for older drugs. Hosp Mater Manage; 1986 May; 11(5):21-2. PubMed ID: 10277138 [No Abstract] [Full Text] [Related]
15. HMM drug price index advances at 4% annual rate. Hosp Mater Manage; 1987 Nov; 12(11):14-5. PubMed ID: 10285402 [No Abstract] [Full Text] [Related]
16. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response. Woolner D N Z Bioeth J; 2003 Oct; 4(3):22, 25-6. PubMed ID: 15597481 [No Abstract] [Full Text] [Related]
17. The use of pharmacy personnel to positively impact hospital finances. Hutchinson RA; Hatoum HT; Kolinski R; Riley DW Hosp Formul; 1989 Aug; 24(8):450, 453. PubMed ID: 10294357 [TBL] [Abstract][Full Text] [Related]
18. The price of innovation: new estimates of drug development costs. DiMasi JA; Hansen RW; Grabowski HG J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142 [TBL] [Abstract][Full Text] [Related]
19. Open versus closed formularies: cost-benefit considerations. Lipman AG Hosp Formul; 1979 Mar; 14(3):380. PubMed ID: 10308844 [No Abstract] [Full Text] [Related]